1-(3,5,6-Trimethylpyridin-2-yl)piperazine → HCID 71252165, Verbindung

HRID 2411614Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 2411614
[O:1]=[S:2]1(=[O:18])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[CH:16]=[CH:15][C:10]([C:11]([O:13]C)=O)=[C:9]([CH3:17])[N:8]=1.[CH3:19][C:20]1[C:21]([N:28]2[CH2:33][CH2:32][NH:31][CH2:30][CH2:29]2)=[N:22][C:23]([CH3:27])=[C:24]([CH3:26])[CH:25]=1>>[O:18]=[S:2]1(=[O:1])[CH2:6][CH2:5][CH2:4][N:3]1[C:7]1[N:8]=[C:9]([CH3:17])[C:10]([C:11]([N:31]2[CH2:32][CH2:33][N:28]([C:21]3[C:20]([CH3:19])=[CH:25][C:24]([CH3:26])=[C:23]([CH3:27])[N:22]=3)[CH2:29][CH2:30]2)=[O:13])=[CH:15][CH:16]=1

Komponenten

3

Edukt 2

HCID 584848231-(3,5,6-Trimethylpyridin-2-yl)piperazineHCID 71252256HCID 71252256, Verbindung

Produkt 1

HCID 71252165HCID 71252165, VerbindungAusbeute 62,4 %

Versuchsvorschrift

Using methyl 6-(1,1-dioxo-1λ6-isothiazolidin-2-yl)-2-methylnicotinate (300 mg) described in Preparation Example 37 and 1-(3,5,6-trimethylpyridin-2-yl)piperazine (251 mg) described in Preparation Example 92 and by the reaction and treatment in the same manner as in Example 109, the title compound (307 mg) was obtained.

Aufarbeitung

  1. customdescribed in Preparation Example 92 and by the reaction and treatment in the same manner as in Example 109

Quellen und Nachweise

ORD-Eintrag
ord-29052010859745d0b4735caf0d28796a
Quelldatensatz
uspto-grants-2014_08
Patentnummer
US08816079B2

Notizen zur Reaktion

Wird geladen…